NCT00685347View on ClinicalTrials.gov

Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol in Pediatric Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

June 30, 2003

Study Completion Date

June 30, 2003

Conditions
AsthmaBronchoconstriction
Interventions
DRUG

Levalbuterol HFA MDI

"1. levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each).~2. Arm #A~3. Xopenex HFA MDI"

DRUG

Racemic Albuterol

"1. racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg).~2. Arm #B~3. Proventil HFA MDI"

Trial Locations (6)

Unknown

Long Beach

Denver

Englewood

Russells Mills

Dallas

Burke

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT00685347 - Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol in Pediatric Subjects | Biotech Hunter | Biotech Hunter